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by CTL Expressing an NK Inhibitory Receptor
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et al., 1995), b-catenin (Robbins et al., 1996), and HLA-France
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by autologous CTL on two melanoma cell lines derived16132 Genova
from metastases that were removed from patient LB33Italy
several years apart (Lehmann et al., 1995). Cell line§ Istituto di Istologia
LB33-MEL.A was obtained after surgery in 1988. A largeUniversita di Genova
number of CTL clones directed against MEL.A cells, aand Dipartimento di Scienze Biomediche
clonal line derived from LB33-MEL.A, were obtained
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with blood lymphocytes collected from the patient in
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1990. Using a method to evaluate the frequency of pre-
25123 Brescia cursors of anti-tumor CTL (CTLp) in the blood of mela-
Italy noma patients, we found that patient LB33 clearly stood
out among 15 patients with a frequency of anti-tumor
CTLp of 1 out of 1000 blood mononuclear cells (Coulie
Summary et al., 1992; P. G. C., unpublished data). In vitro selection
of melanoma cells that were resistant to these CTL
Melanoma lines MEL.A and MEL.B were derived from clones indicated that at least five different antigens were
metastases removed from patient LB33 in 1988 and recognized on the MEL.A cells by autologous CTL.
These antigens are presented by HLA-A28, B13, B44,1993, respectively. The MEL.A cells express several
and Cw6. Antigen LB33-B, presented by HLA-B44 mole-antigens recognized byautologous cytolyticT lympho-
cules, was found to be encoded by a gene that is ex-cytes (CTL) on HLA class I molecules. The MEL.B cells
pressed ubiquitously and that is mutated in the LB33have lost expression of all class I molecules except
melanoma cells (Coulie et al., 1995). The patient re-for HLA-A24. By stimulating autologous lymphocytes
mained disease-free from 1989 until 1993 when a metas-with MEL.B, we obtained an HLA-A24-restricted CTL
tasis was detected and was used to obtain the clonalclone that lysed these cells. A novel gene, PRAME,
cell line MEL.B, which proved resistant to lysis by allencodes the antigen. It is expressed in a large propor-
the CTL clones directed against the MEL.A cells. Thetion of tumors and also in some normal tissues, albeit
MEL.B cells had lost expression of all HLA class I mole-at a lower level. Surprisingly, the CTL failed to lyse
cules except for HLA-A24, suggesting that in patientMEL.A, even though these cells expressed the gene
LB33 the melanoma cells have lost the expression ofPRAME. The CTL expresses an NK inhibitory receptor
several HLA molecules under the selective pressure ofthat inhibits its lytic activity upon interaction with HLA-
an anti-tumor CTL response (Lehmann et al., 1995).Cw7 molecules, which are present on MEL.A cells and
Using MEL.B cells to stimulate blood lymphocytesnot on MEL.B. Such CTL, active against tumor cells
collected from the patient in 1994, we obtained CTLshowing partial HLA loss, mayconstitute an intermedi-
that lysed these cells. CTL clones were derived thatate line of anti-tumor defense between the CTL, which
recognized a new antigen, LB33-E, which is presented
recognize highly specific tumor antigens, and the NK
by HLA-A24 molecules. Surprisingly, the MEL.A cells
cells, which recognize HLA loss variants. were not lysed by these anti-LB33-E CTL (Lehmann et
al., 1995). Here we report the identification of antigen
Introduction LB33-E and provide an explanation for the specificity
of the anti-LB33-E CTL for the MEL.B cells.
During the last 5 years, several human tumor antigens
recognized by autologous cytolytic T lymphocytes (CTL) Results
have been identified. So far three classes of antigen
can be distinguished. The first class comprises antigens A CTL Clone Recognizing MEL.B Cells
encoded by genes, such as MAGE1, MAGE3, BAGE, Blood lymphocytes collected from patient LB33 in 1994
were stimulated in vitro with irradiated MEL.B cells, aand GAGE, that are expressed in tumors of different
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Figure 1. Lytic Activity of CTL Clone 17
(A) Sensitivity of 51Cr-labeled target cells to
lysis by anti-LB33-E CTL clone 17. LB33-
MEL.B-1 (MEL.B) is a clonal subline of the
melanoma cell line LB33-MEL.B derived from
a metastasis resected from patient LB33 in
1993. These cells have lost expression of all
HLA class I molecules except HLA-A24.
LB33-EBV-B is an EBV-transformed B cell
line from patient LB33. Anti-HLA-A24 mono-
clonal antibody C7709A2 was used to inhibit
lysis of MEL.B cells by the CTL by adding a
1:45 dilution of ascitic fluid from mice inocu-
lated with the hybridoma cells.
(B) Inhibition of the lytic activity of CTL 17
by an anti-CD3 monoclonal antibody. Target
cells and CTL were incubated over 2.5 hr in
the absence or presence of anti-CD3 mono-
clonal antibody UCHT-1 (20 mg/ml) or iso-
type-matched anti–interleukin-2 receptor b
antibody CF1, and chromium release was
measured.
clonal line derived from a melanoma metastasis re- the expression of antigen LB33-E into COS-7 cells (Fig-
ure 2A).sected from the patient in 1993. From the responder T
cell population we isolated CTL clone 17, which lysed When a Northern blot prepared with RNA of LB33
melanoma cells was hybridized with cDNA 5E10, a bandMEL.B cells but did not lyse autologous Epstein–Barr
virus (EBV)-transformed B cells or natural killer (NK) tar- of 62.2 kb was observed, suggesting that the 1.5 kb
5E10 clone was incomplete. This cDNA clone was usedget cells K562 (Figure 1A). The antigen recognized by
CTL 17 was named LB33-E. By labeling MEL.B cells with to screen another cDNA library prepared with RNA from
LB33 melanoma cells, and a novel cDNA clone, Hi2, wasanti–HLA class I monoclonal antibodies and measuring
HLA class I gene expression, we observed that these obtained. cDNA Hi2 was 2148 bp long and included
the sequence of cDNA 5E10. Stable transfectants werecells had lost expression of all HLA class I alleles with
the exception of HLA-A24 (Lehmann et al., 1995). As obtained with cDNA Hi2 in a human HLA-A24 leukemia
cell line. They were lysed by CTL 17, indicating that theexpected, an anti-HLA-A24 monoclonal antibody inhib-
ited recognition by CTL 17, indicating that antigen expression of the antigen was not dependent on the high
gene copy number present in COS-7 cells (Figure 2B).LB33-E was presented by HLA-A24 molecules (Figure
1A). The CTL clone was typed TCR ab1, CD31, CD42,
and CD81. An anti-CD3 monoclonal antibody abolished Sequence and Expression of the Gene PRAME
cDNA Hi2 contains an open reading frame encoding athe lysis of MEL.B cells by CTL 17 (Figure 1B), indicating
that the T cell receptor (TCR) of the CTL was involved putative protein of 509 amino acids that has no signal
sequence and shows no significant homology within the recognition of antigen LB33-E.
known proteins (Figure 3). Two parts of cDNA Hi2 were
identical to anonymous sequences present in dataIdentification of a cDNA Coding for Antigen LB33-E
A cDNA library prepared with RNA from LB33 melanoma banks: nucleotides 1486–1589 corresponded to a se-
quence expressed by myeloid leukemia cells K562, andcells was cloned into expression vector pcDNAI/Amp.
This plasmid contains the simian virus 40 (SV40) origin nucleotides 1983–2128 matched a cDNA fragment from
promyelocytic leukemia cells HL-60 (Murakawa et al.,of replication resulting in a high copy number of the
transfected plasmids in COS-7 cells, which express the 1994). In addition, nucleotides 1736–2067 of cDNA Hi2
were 97% homologous to a 332 bp cDNA from humanSV40 T antigen (Seedand Aruffo, 1987). The cDNAlibrary
was divided into 900 pools of about 100 bacteria. Plas- testis (Pawlak et al., 1995). We propose to name PRAME
(for preferentially expressed antigen of melanoma) themid DNA was extracted from each pool and cotrans-
fected into microcultures of COS-7 cells with an HLA- gene that corresponds to cDNAs 5E10 and Hi2.
Northern blots prepared with poly(A)1 RNA of humanA*2402 cDNA clone isolated from the LB33 melanoma
cells. After 24 hr the transfected cells were tested for tumor cell lines and normal tissues were hybridized with
a probe corresponding to cDNA Hi2. Two bands of ap-the expression of antigen LB33-E by adding CTL 17 and
measuring the production of tumor necrosis factor (TNF) proximately 2.2 and 3 kb were observed with the RNA
of several tumor cell lines, including leukemias K562 orafter 24 hr. One pool of cDNA proved positive. It was
subcloned, and cDNA clone 5E10 was found to transfer HL-60, cervical and lung carcinomas, and melanoma
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Absence of Lysis by CTL 17 of Several HLA-A24
Melanoma Lines Expressing PRAME
When we tested the lytic activity of CTL 17 on a panel
of HLA-A24 melanoma cell lines expressing the PRAME
gene at a high level, we observed that some of these
cell lines were sensitive to lysis by the CTL, but several
others were totally resistant (data not shown). Remark-
ably, CTL 17 also failed to lyse MEL.A cells, a clonal
line that was derived from a metastasis resected from
patient LB33 in 1988 (Figure 6A), even though these cells
expressed PRAME and HLA-A24 at the same level as
the MEL.B cells.
A major difference between the MEL.A and MEL.B
cells is that the former also express all the other HLA
class I alleles of patient LB33: A28, B13, B44, Cw6,
and Cw7 (Lehmann et al., 1995). Our observation was
therefore reminiscent of the inhibition of the cytolytic
activity of NK cells, and a fraction of T cells, by major
histocompatibility complex (MHC) class I molecules ex-
pressed on the target cells (Ljunggren and Karre, 1985;
Moretta et al., 1992; Phillips et al., 1995). We therefore
tested the lytic activity of CTL 17 against MEL.A cells
in the presence of a monoclonal antibody recognizing
HLA-B and HLA-C molecules. In these conditions,
Figure 2. Identification of a cDNA Clone Encoding the Antigen Rec- MEL.A cellswere very efficiently lysed by the CTL(Figure
ognized by CTL 17 6A). We concluded that antigen LB33-E was expressed
(A) Stimulation of CTL 17 by COS-7 cells cotransfected with vector by both the MEL.A and MEL.B cells and that HLA-B or
pcDNAI/Amp containing cDNA clone 5E10 and vector pcDNA3 con-
C molecules protected MEL.A from lysis by CTL 17.taining the autologous HLA-A*2402 cDNA. Control stimulator cells
To identify the inhibitory HLA-B or C molecules, weincluded the MEL.B cells and COS-7 cells transfected with HLA-
tested the lytic activity of CTL 17 on MEL.A-1.1.1, anA24 alone. The concentration of TNF released in the medium was
measured using the TNF-sensitive WEHI-164 c13 cells. HLA loss variant derived from MEL.A cells by several
(B) Lysis by CTL 17 of a clone obtained by transfecting HLA-A24 rounds of selection with autologous CTL clones re-
acute lymphocytic leukemia cell line LB804-ALL with expression stricted by HLA-A28 and HLA-B44 molecules. MEL.A-
vector pEF-PL3 containing the cDNA clone Hi2. Control target was
1.1.1 had lost an entire HLA class I haplotype: HLA-A28,the untransfected cell line LB804-ALL.
B44, and Cw7 (Lehmann et al., 1995). These cells were
efficiently lysed by CTL 17 (Figure 6B). No significant
(Figure 4). No bands were obtained with the RNA of inhibition of lysis was observed after transfection of
normal adult tissues except testis. MEL.A-1.1.1 cells with an HLA-B44 construct, whereas
The expression of the PRAME gene in normal tissues transfection with a cDNA clone encoding HLA-Cw7 pro-
was also studied by reverse transcription–polymerase tected these cells from lysis by the CTL. These results
chain reaction (RT–PCR) amplification (Figure 5). As ex- suggested that an inhibitory receptor binding to HLA-
pected based on the results obtained with the Northern Cw7 prevented CTL 17 from lysing MEL.A.
blots, high levels of PRAME expression were found in
testis. Endometrium samples expressed the PRAME
gene at levels corresponding to 5%–30% of that found Involvement of NK Inhibitory Receptor p58.2
Several HLA class I–specific NK cell inhibitory receptorsin the LB33 melanoma cells. Samples of ovary and adre-
nals expressed 2%–5% of that level. Lower levels of have been identified (Moretta et al., 1996). The inhibitory
receptors specific for HLA-C molecules are representedexpression were detected in some samples of other
tissues, including kidney, brain, or skin. We verified that by two members of the p58 molecular family, which
belongs to the immunoglobulin superfamily (Colonnathe sequence of these PCR products amplified from
normal tissues corresponded to that of PRAME. and Samaridis, 1995; Wagtmann et al., 1995; Moretta et
al., 1996). The p58.1 receptors are recognized by theEB6A wide variety of tumor samples expressed the
PRAME gene at a level exceeding 3% of that found in monoclonal antibody and interact with several HLA-C
molecules, including Cw2, 4, and 6 (Moretta et al.,the LB33 melanoma cells (Table 1). The highest propor-
tions of positive tumors were found among melanomas 1990b). The p58.2 receptors are glycoproteins of 58 kDa
recognized by the GL183 antibody. They show specific-(91%), lung squamous cell carcinomas (78%) or adeno-
carcinomas (46%), renal carcinomas (41%), sarcomas ity for a subset of HLA-C molecules that contain serine
and asparagine at positions 77 and 80, respectively,(39%), head and neck squamous cell carcinomas (39%),
and acute leukemias (33%). A high level of gene expres- such as HLA-Cw1, 3, 7, and 8 (Colonna et al., 1993;
Moretta et al., 1993; Biassoni et al., 1995; Colonna,sion, comparable with that found in the LB33 melanoma
cells, was found in most melanoma samples, 24% of 1996).
CTL 17 was labeled with monoclonal antibody GL183,lung squamous cell carcinomas, 35% of sarcomas, and
2% of renal carcinomas. indicating that it carried the p58.2 receptor (Figure 7).
Immunity
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Figure 3. Sequence of cDNA Hi2 and Se-
quence of the Protein Encoded by the Lon-
gest Open Reading Frame
Primers OPC183, OPC184, OPC189, and
OPC190 used for the analysis of PRAME ex-
pression by PCR are indicated by horizontal
arrows. The polyadenylation signal is under-
lined. The LB33-E antigenic peptide is boxed.
The sequence of cDNA 5E10 is delimited by
the square brackets. It contains two NsiI
sites, indicated with vertical arrows, which
were used for the localization of the antigenic
peptide.
The lytic activity of CTL 17 was tested against MEL.A by the CTL. The results indicated that the peptide-cod-
ing region corresponded to nucleotides 1051–1257 ofcells in the presence of antibody GL183, aimed at
blocking the interaction between p58.2 and HLA-Cw7 cDNA Hi2.
This region contained four sequences coding for amolecules (Figure 8). Addition of increasing concentra-
tions of the antibody restored lysis of the MEL.A cells. peptide containing the HLA-A24 binding motif, namely
tyrosine or phenylalanine at position 2 and phenylala-No effect was observed with the isotype-matched
monoclonal antibody EB6, which does not label CTL nine, leucine, isoleucine, or tryptophan at position 9 or
10 (Kubo et al., 1994; Maier et al., 1994). These peptides17 (Figure 7), or with an anti–MHC class II monoclonal
antibody that labels the CTL. These results indicated were synthesized and incubated with EBV-transformed
B cells derived from patient LB33. CTL 17 was added,that blocking the p58.2 receptors on the CTL sup-
pressed the inhibition of lysis of the MEL.A cells. together with the anti-HLA-B or C monoclonal antibody
toblock the inhibition by HLA-Cw7 molecules. Nonapep-Taken together, the results indicate that the MEL.A
cells express the PRAME-encoded antigen,but that they tide LYVDSLFFL sensitized the cells to lysis with a half-
maximal effect at 100 nM (Figure 9). Ten amino acidare not lysed by the anti-PRAME CTL 17 because they
bear HLA-Cw7 molecules, which inhibit the lytic activity peptides with an additional N-terminal or C-terminal res-
idue, or an octamer without the C-terminal leucine resi-of the CTL upon engagement of the NK inhibitory recep-
tor p58.2. As indicated above, CTL 17 recognized its due, were recognized less efficiently (data not shown).
In the absence of the anti-HLA-B or C antibody, EBV-target through a classical ab TCR. We also found that
it did not express FcgRIII (CD16), a receptor expressed transformed B cells from patient LB33 could not be
sensitized at all to lysis by CTL 17, even when highby NK cells (Figure 7).
concentrations of the antigenic peptide were used (Fig-
ure 9).Identification of the LB33-E Antigenic Peptide
To localize the region encoding the antigenic peptide,
cDNA 5E10 was partially digested with NsiI (see Figure Discussion
3), and truncated cDNA clones were cotransfected into
COS-7 cells with the HLA-A24 cDNA clone. The transfec- We have identified a tumor antigen recognized by a CTL
clone on melanoma cells that have lost the expressiontants were tested for the expression of antigen LB33-E
by adding CTL 17 and measuring the production of TNF of several HLA molecules. The gene PRAME, which
CTL Against HLA Loss Melanoma Variant
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Figure 4. Northern Blot Analysis of the Expression of PRAME in Figure 5. Expression of the PRAME Gene Analyzed with RT–PCR
on Normal TissuesTumor Cell Lines and in Normal Tissues
Lanes contained 2 mg of poly(A)1 RNA from tumor cell lines and Expression was tested by reverse transcription of total RNA and
PCR amplification with primers OPC189 and OPC190 shown in Fig-from adult human tissues (Clontech). The three membranes were
hybridized simultaneously with 32P-labeled cDNA Hi2, washed under ure 3. The 561 bp product is not observed when genomic DNA is
tested. A semi-quantitative measurement was obtained by combin-stringent conditions, and autoradiographed over 10 days to detect
a low level of expression in the normal tissues. Control hybridization ing a limiting number of PCR cycles, comparing the result with a
standard curve of RNA from MEL.A cells, and making a correctionwas performed on the same membranes with a b-actin probe.
for the integrity of the RNA by taking into account the expression
level of the b-actin gene. Each point represents the level of PRAME
expression found in a sample of normal tissue. The results are ex-codes for this antigen, is expressed in most melanomas
pressed relative to the level of expression of the PRAME gene mea-and lung squamous cell carcinomas and also in many
sured in the MEL.A cells, which is equivalent to that measured in
sarcomas and acute leukemias. It shows a low level of the MEL.B cells. The limit of detection is indicated with a broken
expression in many normal tissues and an intermediate line.
level in adrenals, ovary, and endometrium. The CTL
clone that recognizes the PRAME-encoded antigen is
remarkable in that, owing to the presence of a NK inhibi- characteristics with that of genes of the MAGE, BAGE,
and GAGE families. All of these genes are expressed intory receptor, it does not lyse cells that present the
target antigen if they also bear the HLA-Cw7 molecule. tumors of many different histological types. However,
PRAME is expressed by a higher proportion of samplesOur observation that anti-PRAME CTL could be derived
from LB33 lymphocytes collected in 1994 but not in 1990 than any of the other genes, and it is also expressed
by acute myeloid leukemias, which never express the(Lehmann et al., 1995) suggests that an anti-PRAME
response occurred in vivo and provided CTL that could MAGE, BAGE, or GAGE genes (Chambost et al., 1993;
Shichijo et al., 1996). A second similarity among all thesebe restimulated in vitro. It will be interesting to find out
whether or not anti-PRAME CTL always carry NK inhibi- genes is their high level of expression in testis. The
mouse gene family SMAGE, which is homologous to thetory receptors. Considering the expression of PRAME
in some normal tissues, it may well be that anti-PRAME human MAGE gene family, is expressed in testis by
germinal cells (Chomez et al., 1995), and the MAGE1CTLp devoid of the inhibitory receptor undergo some
form of tolerance. If this is the case, only anti-PRAME and MAGE4 proteins were detected in human spermato-
gonia and spermatocytes (Takahashi et al., 1995). It isCTL with inhibitory receptors will be found. The alterna-
tive is that anti-PRAME CTLp with or without inhibitory possible that the expression of PRAME in testis will also
be restricted to germinal cells, which do not bear HLAreceptor can be activated in vivo and that the response
against the MEL.B cells, which have lost HLA-Cw7, hap- molecules and should therefore not suffer from an anti-
PRAME T cell response.pened to involve a CTL clone carrying the inhibitory
receptor. In this case, anti-PRAME responses involving The activation of the MAGE1 gene in tumor cells ap-
pears to be due to the demethylation of the promoter,lymphocytes devoid of inhibitory receptor may be ob-
served in other patients. and this was correlated with a genome-wide demethyl-
ation process (De Smet et al., 1996). We observed thatThe expression of the PRAME gene shares several
Immunity
204
Table 1. Expression of PRAME by Tumor Tissues
Tumor Samples n Percent
Brain tumors 1 of 7
Colorectal carcinomas 2 of 51
Gastric carcinomas 1 of 2
Melanomas
Primary lesions 43 of 49 88
Metastases 144 of 152 95
Ocular 5 of 9
Neuroblastomas 2 of 3
Head and neck squamous carcinomas 17 of 44 39
Lung carcinomas
Small cell lung carcinomas 1 of 4
Non–small cell lung carcinomas
Adenocarcinomas 12 of 26 46
Squamous cell carcinomas 51 of 65 78
Prostatic carcinomas 2 of 20
Renal carcinomas 24 of 58 41
Bladder tumors
Superficial 4 of 36
Infiltrating 9 of 42
Sarcomas 9 of 23 39
Mammary carcinomas 45 of 169 27
Thyroid carcinomas 3 of 5
Acute leukemias 21 of 63 33
Tumor Cell Lines n Percent
Melanomas 72 of 74 97
Sarcomas 4 of 5
Lung carcinomas: Figure 6. Inhibition of the Lytic Activity of CTL 17 by HLA Class I
Molecules Expressed on the Target CellsSmall cell lung carcinomas 19 of 27 70
Non small cell lung carcinomas 2 of 2 (A) Cytolytic activity of anti-PRAME CTL17 onautologous melanoma
Mesotheliomas 2 of 18 cells MEL.A, a clonal subline of the melanoma cell line LB33-MEL.A
Head and neck tumors 2 of 7 derived from patient LB33 in 1988. These cells express HLA-A24,
Bladder tumors 2 of 3 A28, B13, B44, Cw6, andCw7. Anti-HLA-B or C monoclonalantibody
Colorectal carcinomas 1 of 15 B1.23.2 was added in the lysis assay as a 1:60 dilution of ascitic
Renal carcinomas 9 of 12 fluid from mice inoculated with the hybridoma cells.
EBV-transformed B cell lines 0 of 8 (B) Cytolytic activity of CTL 17 on MEL.A-1.1.1 cells. MEL.A-1.1.1
is a variant, derived from the MEL.A cells, selected in vitro for resis-Expression of the PRAME gene was tested by RT–PCR amplification
tance to autologous CTL clones 159/3 and 159/5. It has lost theof total RNA with primers OPC183 and OPC184 shown in Figure 3.
expression of a complete HLA haplotype: HLA-A28, B44, and Cw7.The amplified product of 1191 bp was not observed when genomic
The MEL.A-1.1.1 cells were transfected with the autologous HLA-DNA was tested. A semi-quantitative measurement was obtained
B*4402 or HLA-Cw*0704 alleles cloned into expression vectors, andas indicated in Figure 5, and samples were scored positive if their
clonal lines isolated from the transfected populations were testedexpression of the PRAME gene exceeded 3% of that found in MEL.A
for their sensitivity to lysis by CTL 17.cells.
by the expression of MHC class Imolecules on the target
cells (Ljunggren and Karre, 1985; Moretta et al., 1992),the treatment of primary fibroblasts or phytohemaggluti-
and HLA-specific NK cell inhibitory receptors have beennin A–stimulated blood mononuclear cells with de-
identified (Moretta et al., 1996). Inhibitory receptors weremethylating agent 5-aza-29-deoxycytidine activated the
MAGE1 gene and also the PRAME gene (data not
shown). This effect of DNA demethylation may explain
why PRAME is expressed in testis, since male germline
cells undergo a genome-wide demethylation.
In contrast with the MAGE genes, PRAME is ex-
pressed in some normal tissues other than testis. Except
for endometrium, which expresses up to 30% of the
level found in the LB33 melanoma cells, the levels of
expression in normal tissues corresponded to less than
3%–5% of that found in melanoma cells. We have ob-
served that anti-MAGE1 CTL were unable to recognize
tumor cell lines that expressed MAGE1 at levels corre-
sponding to less than 5% of that found in the melanoma Figure 7. Expression of Surface Antigens by CTL 17
cells that were efficiently lysed (B. L., unpublished data).
Cells were incubated with the indicated murine monoclonal antibod-
It is therefore possible that the expression of PRAME ies or without antibody, washed, labeled with goat anti–mouse im-
in most normal tissues is insufficient for CTL recognition. munoglobulin antibodies coupled to fluorescein, and analyzed by
flow cytometry.It is well established that lysis by NK cells is inhibited
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Figure 8. Lytic Activity of CTL 17 against MEL.A Cells in the Pres- Figure 9. Lysis by CTL 17 of Autologous EBV-Transformed B Cells
ence of an Anti-p58.2 Antibody Incubated with the PRAME-Encoded Peptide LYVDSLFFL
CTL 17 (10,000 cells per well) were incubated for 30 min at 48C 51Cr-labeled EBV-transformed B cells from patient LB33 were incu-
with the indicated concentrations of anti–p58.2 IgG1 monoclonal bated first for 30 min at 48C with anti-HLA-B or C monoclonal anti-
antibody GL183 (closed circles), anti–p58.1 IgG1 monoclonal anti- body B1.23.2 (closed circles; 1:50 dilution of ascitic fluid from mice
body EB6 (open triangles), or anti–MHC class II IgG2a monoclonal inoculated with the hybridoma cells) or without antibody (open cir-
antibody L243 (open circles). 51Cr-labeled MEL.A cells were then cles) and then for 30 min at 208C with the indicated concentrations
added (1000 cells per well) and chromium release was measured of peptide. CTL 17 were then added at an E:T ratio of 10:1, and
after 4 hr. chromium release was measured after 4 hr.
frequently observed in tumors and may often result fromalso shown tobe present on a small fraction of T lympho-
selection by anti-tumor T cell responses (Smith et al.,cytes (Falk et al., 1995; Mingari et al., 1995, 1996; Phillips
1989; Garrido et al., 1995). The anti-tumor CTL with in-et al., 1995). The anti-PRAME CTL 17 bears the p58.2
hibitory receptors may therefore play a role after theinhibitory receptor, which recognizes HLA-Cw1, 3, 7,
classical CTL that recognize tumor-specific antigensand 8 (Colonna et al., 1993; Biassoni et al., 1995). This
presented by HLA class I molecules and before NK cells,explains why CTL 17 could not lyse some allogeneic
which usually express multiple inhibitory receptors andHLA-A24 melanomas that expressed PRAME. These tu-
may therefore preferentially target tumor cells that havemor cell lines were derived from patients expressing
completely lost the expression of MHC class I mole-one of the HLA-C alleles that bind p58.2, and they could
cules. It is possible that some tumor-specific CTL bear-be lysed by CTL 17 in the presence of an anti-HLA-B or
ing inhibitory receptors will prove to recognize, on tumorC antibody (data not shown). It is worth noting that CTL
cells showing partial HLA loss, antigenic peptides that17 does not lyse the prototype NK target K562 (Figure
are expressed ubiquitously but are not recognized by1), indicating that although it bears an inhibitory receptor
these CTL on normal cells that express all HLA class Ipresent on NK cells, it does not exert the MHC-nonre-
molecules.stricted lytic activity of these cells.
Two cDNA clones (clone 6 and clone 43) encoding
Experimental Proceduresp58.2 receptors have been reported (Wagtmann et al.,
1995). The sequence of the p58.2 transcript present in Cell Lines
CTL 17 encodes a mature protein of 327 residues that The clinical course of melanoma patient LB33 (HLA-A24, A28, B13,
B44, Cw6, Cw7) and the characterization of the various LB33-MELis identical to that coded by the p58 cDNA clone 43
clonal cell lines and antigen-loss variants have been described (Leh-(GenBank number U24075) with the exception of two
mann et al., 1995). Melanoma cell line LB33-MEL.A was derivedamino acids. Residue 312 of the mature protein, located
from a cutaneous metastasis resected from patient LB33 in 1988.in the C-terminal ITIM (immunoreceptor tyrosine-based
Clonal cell line LB33-MEL.A-1 (MEL.A) was derived from it by limiting
inhibition motif), is alanine in the published sequence dilution. Melanoma cell line LB33-MEL.B was derived from an intesti-
and threonine in the cDNA of CTL 17. This threonine nal metastasis resected in 1993 and used to derive clonal cell line
LB33-MEL.B-1 (MEL.B) (Lehmann et al., 1995). One of the antigensresidue is the consensus found in the other reported
recognized by autologous CTL on the MEL.A cells is encoded by ap58.1 and p58.2 sequences. The second difference is
gene that is mutated in the MEL.A and MEL.B cells, but not in theresidue 200 of the mature protein: the isoleucine of p58
normal cells of patient LB33 (Coulie et al., 1995). This demonstratesclone 43 is replaced here by threonine, which is also
that MEL.A and MEL.B cells derive from the same tumor. Pre-B
the consensus found in the other p58 sequences. This acute lymphocytic leukemia cell line LB804-ALL was derived from
amino acid is located in the C-terminalpart of thesecond an HLA-24 patient. With the exception of LB804-ALL, all the tumor
cell lines were cultured with Iscove’s medium (GIBCO Laboratories,immunoglobulin domain, 25 residues apart from the
Grand Island, NY) containing 10% FCS (GIBCO), supplemented withtransmembrane region.
L-arginine (116 mg/l), L-asparagine (36 mg/l), and L-glutamine (216CTL 17 may be representative of a novel category
mg/l). LB804-ALL cells were cultured in Iscove’s medium containingof anti-tumor T lymphocytes, situated between tumor-
10% human serum. COS-7 cells (American Type Culture Collection
specific CTL and NK cells, that shows specificity for [ATCC], Rockville, MD) were maintained in DMEM (GIBCO) with 10%
tumor cells that have lost expression of some, but not FCS. WEHI-164c13 cells (Espevik and Nissen-Meyer, 1986) were
cultured in RPMI-1640 (GIBCO) with 5% FCS.all, HLA class I molecules. Such partial HLA losses are
Immunity
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Anti-Tumor CTL Clones and 39 ends of published sequences (Colonna and Samaridis, 1995;
D’Andrea etal., 1995; Wagtmann et al., 1995): 59-CACCATGTCGCTCBlood mononuclear cells of patient LB33 were isolated by Lympho-
prep (Nycomed, Oslo, Norway) density-gradient centrifugation and ATGGTCGTCA-39 (sense) and 59-GACAGGGCTGTTGTCTCCCTAG-39
(antisense). PCR conditions were 5 min at 948C, followed by 32cryopreserved. Autologous mixed lymphocyte tumor cell cultures
(MLTC) and derivation and long-term culture of CTL clones were cycles of amplification (948C for 1 min, 648C for 2 min, and 728C for
3 min) using the Pfu DNA polymerase (Stratagene, La Jolla, CA),carried out as described previously (Lehmann et al., 1995). Anti-
LB33-E CTL clone LB33-CTL-269/17, referred to in this report as and followed by an incubation of 15 min at 728C with the AmpliTaq
DNA polymerase (Roche Molecular Systems, Branchburg, NJ). TheCTL 17, was derived from lymphocytes collected in 1994 and stimu-
lated with MEL.B cells. Anti-LB33-E CTL clone LB33-CTL-269/1, amplifiedproducts werecloned into plasmid pCR3using the Eukary-
otic TA Cloning Kit (Invitrogen) and sequenced. In addition to awhich we described previously (Lehmann et al., 1995), was derived
from the same population of MLTC responder cells as CTL 17. CTL p58.2 cDNA clone, CTL 17 expressed sequences corresponding to
other members of the immunoglobulin-related family of NK recep-17 was chosen for further experiments because it showed a better
rate of proliferation than CTL clone 269/1. tors such as the p50.3 or pKKA3 (GenBank number X94609; Bottino
et al., 1996) and the p70 NKAT4 (GenBank number L41270; ColonnaSensitivity of target cells to lysis by the CTL was evaluated by
a standard 51Cr-release assay over 4 hr. Target tumor cells were and Samaridis, 1995). The presence of these molecules on CTL 17
could not be detected using several of the available monoclonalincubated for 48 hr in culture medium supplemented with IFNg (50
U/ml; Boehringer Mannheim, Mannheim, Federal Republic of Ger- antibodies.
many). The TNF secretion assay was performed as described pre-
viously (Lehmann et al., 1995). Some lysis assays were performed DNA Sequencing and Homology Search
in the presence of the following murine monoclonal antibodies: DNA sequencing was performed with the DTaq cycle sequencing
C7709A2, an anti–HLA-A24 immunoglobulin G2a (IgG2a) obtained kit (United States Biochemical, Cleveland, OH). Computer search
in our laboratory; B1.23.2, an anti–HLA-B or C IgG2a (Lemonnier et for sequence homology was done with programs FASTA@EMBL–
al., 1982; Rebai and Malissen, 1983); L243, an anti–HLA-DR IgG2a Heidelberg and blast@ncbi.nlm.nih.gov. The sequence of cDNA
obtained from ATCC; EB6 and GL183, anti–p58.1 and anti–p58.2 clone 5E10 (1554 bp) was totally included into that of cDNA clone
IgG1, respectively (Moretta et al., 1990a, 1990b); UCHT1 and CF1, Hi2 (2148 bp). The overlapping sequences were identical with the
anti–CD3 and anti–CD122 IgG1, respectively (Immunotech, Mar- exception of one nucleotide, T at position 254 in cDNA Hi2 versus
seille, France). Peptides were synthesized by conventional solid- C in 5E10. The two sequences may correspond to two PRAME
phase peptide synthesis, using Fmoc for transient N-terminal alleles expressed in MEL.A cells.
protection (Atherton et al., 1981), and characterized by mass spec-
trometry. They were solubilized at 20 mg/ml in DMSO, kept frozen Northern Blot Analysis
at 2208C, and diluted in Iscove’s medium immediately before use. Nylon membranes with UV-fixed poly(A)1 RNA (2 mg per lane) ex-
tracted from normal adult tissues and from tumor cell lines (Clon-
Construction and Screening of the cDNA Library tech, Palo Alto, CA) were prehybridized for 4 hr at 658C in 53 SSPE
The cDNA library was constructed as described previously (Coulie (203 SSPE is 3 M NaCl, 0.2 M NaH2PO4, 0.5 M EDTA [pH 7.4]), 103
et al., 1994). In brief, poly(A)1 RNA was isolated from MEL.A cells Denhardt’s solution, and 2% SDS and hybridized overnight at 658C
with the mRNA extraction kit Fastrack (Invitrogen Corporation, in the same solution containing 1.3 3 106 cpm per milliliter of a 32P-
Oxon, United Kingdom). It was converted to cDNA by using random labeled cDNA Hi2 probe and 100 mg/ml herring sperm DNA. The
primers. The cDNA was ligated to BstXI adaptors (Invitrogen) and membranes were washed once at room temperature in 23 SSC,
inserted into the BstXI sites of expression vector pcDNAI/Amp (In- 0.05% SDS and two times for 20 min at 508C in 0.13 SSC, 0.1%
vitrogen), as described in the SuperScript plasmid system kit SDS and then autoradiographed.
(GIBCO BRL, Gaithersburg, MD). Recombinant plasmids were
transfected by electroporation into E. coli DH5a and selected with
PCR Assay for PRAME Expressionampicillin (50 mg/ml). The library was divided into 900 pools of about
Total RNA extraction, reverse transcription of RNA, and PCRamplifi-100 cDNA clones.Each pool was amplified to saturationand plasmid
cations were performed as described previously (Van den Eynde etDNA was extracted. COS-7 cells (2 3 104 per well) were cotrans-
al., 1995). For the analysis of PRAME expression in tumor samples,fected using the DEAE–dextran–chloroquine method (Seed and
PCR primers were OPC183 and OPC184, shown in Figure 3, andAruffo, 1987), with about 100 ng of plasmid DNA of a pool of the
PCR conditions were 5 min at 948C, followed by 30 cycles consistingcDNA library and with 100 ng of plasmid pcDNA3 (Invitrogen) con-
of 1 min at 948C, 2 min at 658C, and 3 min at 728C. We verified thattaining an HLA-A*2402 cDNA isolated from the MEL.A cells (Leh-
with these conditions we were in the linear range of DNA amplifica-mann et al., 1995). Transfected COS-7 cells were tested in a CTL
tion. The size of the product amplified from cDNA (1191 bp) couldstimulation assay after 24 hr.
be distinguished from that amplified from contaminating DNA (.2.6
kb). The quality of RNA preparations was tested by PCR amplifica-Transfection of Tumor Cell Lines
tion of a human b-actin sequence. The quantities of the amplifiedMelanoma clonal line LB33-MEL.A-1.1.1 (MEL.A-1.1.1) (Lehmann et
DNA were visually assessed with agarose gels stained with ethidiumal., 1995) was transfected by the calcium phosphate precipitation
bromide. They were compared with the products of RT–PCR amplifi-method, as described previously (Traversari et al., 1992b). In brief,
cations of serial dilutions (1:1, 1:3, 1:9, and 1:27) of RNA from MEL.A1.2 3 106 cells were transfected with 30 mg of plasmid pcDNA3
cells. The level of expression of each sample was normalized forcontaining an HLA-B*4402 cDNA or of vector pEF-PL3 containing an
RNA integrity by taking into account the expression level of theHLA-Cw*0704 cDNA. Plasmid pEF-PL3, provided by J.-C. Renauld
b-actin gene. For the analysis of PRAME expression in normal tis-(Ludwig Institute, Brussels), was derived from pEF-BOS (Mizushima
sues, we sought a more sensitive detection and performed PCRand Nagata, 1990) by insertion of a puromycin resistance gene. The
amplifications with more cycles. We observed that in these condi-HLA cDNAs were isolated from the MEL.A cells (Lehmann et al.,
tions nonspecific products were sometimes amplified with primers1995). Clonal transfectants were isolated from the G418-resistant
OPC183 and OPC184. We resorted to the use of another pair of(1.5 mg/ml) or puromycin-resistant (0.7 mg/ml) populations. Acute
primers, OPC189 and OPC190 (Figure 3), that allowed the specificleukemia cell line LB804-ALL, derived from patient LB804 (HLA-A2,
amplification of a 561 bp fragment of PRAME. The size of the productA24, B35,B62, Cw3, Cw4) does not express the PRAME gene. These
amplified from contaminating DNA was different. PCR conditionscells were transfected by electroporation with 50 mg of cDNA Hi2
were 5 min at 948C followed by 34 cycles consisting of 30 s at 948C,cloned into expression vector pEF-PL3. A clone was isolated by
2 min at 648C, and 3 min at 728C. The quantities of amplified DNAlimiting dilution from the puromycin-resistant (0.5 mg/ml) population.
were compared with those obtained with a standard curve con-
taining the products of RT–PCR amplifications of serial dilutionsCloning the p58/p70 Sequences Expressed by CTL 17
(1:128, 1:256, 1:512, and 1:1024) of RNA from MEL.A cells. TheRNA extracted from CTL 17 with the TRIzol reagent (GIBCO BRL)
expression of samples was normalized for RNA integrity as above,was converted to cDNA using oligo(dT) primers. Sequences corre-
and the results were expressed relative to the level of expressionsponding to known p58.1, p58.2, or p70 products were amplified
by PCR using oligonucleotides deduced from the leader sequences by MEL.A cells.
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